International journal of thyroidology

Korean Thyroid Association (대한갑상선학회)
권호 표지
DOI QR코드

DOI QR Code

Adverse Events of Tyrosine Kinase Inhibitors in Patients with Advanced Thyroid Cancer

진행성 갑상선암 환자에서 발생하는 Tyrosine Kinase Inhibitor의 이상반응

  • Kim, Min Joo (Department of Internal Medicine, Seoul National University Hospital) ;
  • Park, Young Joo (Department of Internal Medicine, Seoul National University Hospital)
  • Received : 2018.10.15
  • Accepted : 2018.11.16
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Tyrosine kinase inhibitors (TKIs) are widely used for the treatment of advanced radioiodine-refractory thyroid cancer. Although the previous studies including large-scale randomized controlled trials have demonstrated the effects of TKIs in advanced thyroid cancers, it has been found that most patients experienced adverse events (AEs). Unlike other cancers, even patients with advanced thyroid cancers are often asymptomatic. Rather, TKI use can make patients suffer adverse events. Therefore, the use of TKI should be decided after the full consideration of AEs as well as its efficacies. While using TKI, AEs should be monitored, evaluated, and managed appropriately, if AEs develop. In this review, the occurrence, evaluation, and management of AEs of sorafenib, lenvatinib, and vandetanib will be described, which TKIs are most commonly used for the treatment of advanced thyroid cancer. Some suggestions for the management of AEs in the real life are also provided.

Keywords

References

  1. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319-28. https://doi.org/10.1016/S0140-6736(14)60421-9
  2. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621-30. https://doi.org/10.1056/NEJMoa1406470
  3. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41. https://doi.org/10.1200/JCO.2011.35.5040
  4. National Cancer Institute. Protocol development: Cancer Therapy Evaluation Program 2017.
  5. Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, et al. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer 2015;22(6):877-87. https://doi.org/10.1530/ERC-15-0252
  6. Jean GW, Mani RM, Jaffry A, Khan SA. Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers. JAMA Oncol 2016;2(4):529-34. https://doi.org/10.1001/jamaoncol.2015.5927
  7. Shen CT, Qiu ZL, Luo QY. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer 2014;21(2):253-61. https://doi.org/10.1530/ERC-13-0438
  8. Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, et al. Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study. Thyroid 2018;28(3):340-8. https://doi.org/10.1089/thy.2017.0356
  9. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017;56(1):121-8. https://doi.org/10.1007/s12020-017-1233-5
  10. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, et al. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 2015;106(12):1714-21. https://doi.org/10.1111/cas.12826
  11. Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the Phase III SELECT trial. J Clin Oncol 2017;35(23):2692-9. https://doi.org/10.1200/JCO.2016.71.6472
  12. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 2015;121(16):2749-56. https://doi.org/10.1002/cncr.29395
  13. Jasim S, Iniguez-Ariza NM, Hilger CR, Chintakuntlawar AV, Ryder MM, Morris JC 3rd, et al. Optimizing lenvatinib therapy in patients with metastatic radioactive iodine-resistant differentiated thyroid cancers. Endocr Pract 2017;23(10):1254-61. https://doi.org/10.4158/EP171822.OR
  14. Berdelou A, Borget I, Godbert Y, Nguyen T, Garcia ME, Chougnet CN, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 2017. [Epub ahead of print]
  15. Bastholt L, Kreissl MC, Fuhrer D, Maia AL, Locati LD, Maciel L, et al. Effect of an outreach programme on vandetanib safety in medullary thyroid cancer. Eur Thyroid J 2016;5(3):187-94. https://doi.org/10.1159/000448919
  16. Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 2015;25(4):386-91. https://doi.org/10.1089/thy.2014.0361
  17. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28(5):767-72. https://doi.org/10.1200/JCO.2009.23.6604
  18. Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 2013;98(6):2401-8. https://doi.org/10.1210/jc.2013-1115
  19. Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012;148(12):1418-20. https://doi.org/10.1001/2013.jamadermatol.192
  20. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 2013;98(1):31-42. https://doi.org/10.1210/jc.2012-2909
  21. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015;112(2):296-305. https://doi.org/10.1038/bjc.2014.564
  22. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36(5):295-316. https://doi.org/10.1007/s40264-013-0047-5
  23. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, et al. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 2014;19(5):477-82. https://doi.org/10.1634/theoncologist.2013-0409
  24. ClinicalTrials.gov. A phase 2 trial of lenvatinib (E7080) in subjects with iodine-131 refractory differentiated thyroid cancer to evaluate whether an oral starting dose of 18 mg daily will provide comparable efficacy to a 24 mg starting dose, but have a better safety profile. [cited November 17, 2018]. Available from: https://clinicaltrials.gov/ct2/show/NCT02702388.
  25. Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M, Network T. Treatment of refractory thyroid cancer. Endocr Relat Cancer 2018;25(4):R209-R23. https://doi.org/10.1530/ERC-17-0542
  26. Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab 2014;99(12):4390-6. https://doi.org/10.1210/jc.2014-2811